Author

Alfredo Papa

ASSESSMENT OF LOSS OF RESPONSE TO INFLIXIMAB THERAPY IN INFLAMMATORY BOWEL DISEASES USING ANTIBODIES TO INFLIXIMAB AND TROUGH LEVELS.

Luisa Guidi, Manuela Marzo, Carla Felice, Daniela Pugliese, Gianluca Andrisani, Giammarco Mocci, Olga Maria Nardone, Gian Lodovico Rapaccini, Alfredo Papa, Alessandro Armuzzi, Gian Lodovico Rapaccini

CHARACTERIZATION OF MUCOSAL CYTOKINE PROFILE IN ULCERATIVE COLITIS PATIENTS UNDER CONVENTIONAL AND ANTI-TNF-A TREATMENT

Loris Riccardo Lopetuso, Franco Scaldaferri, Valentina Petito, Cristina Graziani, Federica Castri, Matteo Neri, Alessandro Sgambato, Antonio Gasbarrini, Alfredo Papa

COMBINATION THERAPY PREDICTS LONG-TERM MUCOSAL HEALING IN MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH ANTI TNF-?

Daniela Pugliese, Pietro Manuel Ferraro, Carla Felice, Gian Lodovico Rapaccini, Alfredo Papa, Luisa Guidi, Alessandro Armuzzi

DEEP REMISSION IMPROVES CLINICAL OUTCOMES AFTER INFLIXIMAB DISCONTINUATION IN INFLAMMATORY BOWEL DISEASES

Carla Felice, Daniela Pugliese, Manuela Marzo, Gianluca Andrisani, Olga Maria Nardone, Alfredo Papa, Italo De Vitis, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi

Early Vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Elisa Gremese, Barbara Tolusso, Clara Di Mario, Alfredo Papa, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION

Laura Parisio, Carlo Romano Settanni, Daniele Napolitano, Simone Varca, Elisa Schiavoni, Lucrezia Laterza, Loris Riccardo Lopetuso, Marco Pizzoferrato, Stefano Bibbò, Norma Alfieri, Luisa Guidi, Alfredo Papa, Antonio Gasbarrini, Alessandro Armuzzi, Daniela Pugliese, Franco Scaldaferri

EPIDEMIOLOGY OF DIVERTICULAR DISEASE OF THE COLON: AN ANALYSIS FROM THE INTERNATIONAL “DICA” PROSPECTIVE STUDY

Antonio Tursi, Giovanni Brandimarte, Francesco Di Mario, Walter Elisei, Marcello Picchio, Leonardo Allegretta, Maria Laura Annunziata, Mauro Bafutto, Gabrio Bassotti, Maria Antonietta Bianco, Rita Luisa Conigliaro, Simona Grad, Silvio Danese, Dan Lucian Dumitrascu, Ricardo Escalante, Roberto Faggiani, Marilisa Franceschi,

INFLIXIMAB LEVEL AND ANTI-DRUG ANTIBODY IN INFLAMMATORY BOWEL DISEASE PATIENTS LOSING RESPONSE: ASSAY AFTER OPTIMIZATION AND OUTCOME AT ONE YEAR.

Luisa Guidi, Manuela Marzo, Barbara Tolusso, Daniela Pugliese, Gianluca Andrisani, Carla Felice, Rosario Landi, Silvia Canestri, Elisa Gremese, Italo De Vitis, Alfredo Papa, Gian Lodovico Rapaccini, Alessandro Armuzzi

INTESTINAL AND EXTRA-INTESTINAL CANCER IN IBD PATIENTS ADMITTED TO AN ITALIAN TERTIARY CENTRE

Gianenrico Rizzatti, Maria Teresa Pistone, Andrea Poscia, Veronica Ojetti, Loris Riccardo Lopetuso, Marco Pizzoferrato, Gianluca Ianiro, Massimo Volpe, Elisa Schiavoni, Eleonora Gaetani, Alessandro Sgambato, Francesco Franceschi, Alfredo Papa, Giovanni Cammarota, Antonio Gasbarrini, Franco Scaldaferri

LONG-TERM COMBINATION THERAPY WITH INFLIXIMAB AND AZATHIOPRINE PREDICTS SUSTAINED STEROID-FREE CLINICAL BENEFIT IN STEROID-DEPENDENT ULCERATIVE COLITIS

Alessandro Armuzzi, Daniela Pugliese, Silvio Danese, Gianluca Rizzo, Manuela Marzo, Carla Felice, Gianluca Andrisani, Gionata Fiorino, Italo De Vitis, Gian Lodovico Rapaccini, Alfredo Papa, Luisa Guidi, Olga Maria Nardone, Gian Lodovico Rapaccini

Item 1 - 10 / 48
1
2 3 4 5